Relative to other companies, Brexit could disproportionately affect Valeant (VRX) due to inherent exchange-rate risk. About a third of the company’s revenue comes from outside North America, which could cause earnings to suffer with exchange rate headwinds factored in. (The GBP/USD normally trades at 1.50-1.60, but has settled to 1.35 in these few days after the Brexit vote.) Current consensus for Q2 2016 seems to come in around 1.60-1.65 with 1.75-1.80 for Q3. Valeant is also currently in the midst of attempting to sell off any valuable, divestible assets to help pay off its massive debt load that had been accumulated during its acquisition-based growth strategy. The economic uncertainty surrounding the UK’s vote to leave the EU could potentially make any deals harder to come by. It could look to IPO its eye-care subsidiary Bausch & Lomb or sell the company outright. Valeant bought the company for $8.7 billion three years ago, but that segment has recently faced declining revenues, making breakeven or better on the investment less likely.